Stem cell therapy presents a promising and more affordable alternative for individuals suffering from Multiple Sclerosis (MS), including those diagnosed with Primary Progressive Multiple Sclerosis (PPMS) or Relapsing-Remitting Multiple Sclerosis (RRMS).

Given the significant financial burden imposed by the high costs of traditional treatments like Ocrevus, the pursuit of cost-effective solutions such as stem cell therapy is essential.

The affordability and accessibility of effective treatments are crucial for improving the quality of life for MS patients, positioning stem cell therapy as a notably more economical option worth exploring.

‍

{{protocol="/styling"}}

‍

Is Stem Cell Therapy More Affordable Than Ocrevous?

Stem cell therapy and Ocrevus are two different treatment options for multiple sclerosis (MS), with significant differences in cost:Stem Cell Therapy:

• The annual cost of stem cell therapy ranges between $20,000 to $35,000
• Stem cell therapy is typically a one-time treatment that has the potential to provide lasting relief from MS symptoms

Ocrevus:

• The average retail price of Ocrevus is around $7,800 per 300mg/10mL vial
• The annual cost of Ocrevus can be over $65,000 per year
• Ocrevus is administered by intravenous infusion every 6 months and requires long-term use

‍

In comparison, the annual cost of stem cell therapy ($20,000 to $35,000) is significantly lower than the annual cost of Ocrevus (over $65,000). Additionally, stem cell therapy is a one-time treatment, while Ocrevus requires ongoing infusions every 6 months, leading to higher long-term costs

‍

However, it's important to note that stem cell therapy for MS is still an experimental treatment and has not been approved by the FDA in the United States5. More research and clinical trials are needed to fully understand its long-term effectiveness and safety compared to FDA-approved treatments like Ocrevus.

Potential benefits of stem cell therapy for MS

Before discussing the potential benefits of stem cell therapy for MS, it's essential to understand what Multiple Sclerosis is. MS is an autoimmune disease that attacks the protective coating around nerve fibers in the spinal cord - this coating is called the myelin sheath. This damage to the myelin sheath surrounding the nerves can cause loss of muscle function and difficulty with normal bodily functions such as vision, speech, movement, and digestion. Stem cell therapy has shown promise in fighting the effects of Multiple Sclerosis by repairing and replacing the myelin sheath surrounding the nerves. This occurs due to the anti-inflammatory and immune regulation attributes of Mesenchymal Stem Cells (MSCs) used in stem cell therapies.

Stem cell therapy could also be used to promote the growth of new neurons and help repair damage caused by the autoimmune attack on the nerves. In addition to treating the physical effects of MS, stem cell therapy could also help those with MS to live a healthier and more fulfilling lifestyle. Stem cell therapy could reduce the frequency and duration of MS flare-ups, allowing people with MS to live a less restricted and fulfilling lifestyle. Condition stabilization could also help reduce the cost of treatment for those with MS, as less frequent and shorter flare-ups could lessen the need for expensive treatments like Ocrevous.

‍

Overview of traditional MS treatments

Multiple Sclerosis (MS) is a chronic illness characterized by inflammation and nerve damage. The FDA has approved several treatments aiming to minimize the frequency and severity of MS flare-ups. Ocrevus (ocrelizumab) and Lemtrada (alemtuzumab) are two primary options, each with unique approaches and associated costs. These treatments have been effective in reducing MS symptoms but may be financially inaccessible for uninsured patients.

‍

{{apply="/styling"}}

‍

Ocrevus (Ocrelizumab): A Bi-Annual Infusion for MS

• Mechanism: Targets B-cells in the immune system responsible for MS-related inflammation and nerve damage.
• Administration: Infusions every six months.
• Benefits: Reduces relapse rates and slows disability progression.
• Side Effects: Include rash, itching, hives, headache, nausea, and infusion-related reactions.
• Cost: Can exceed $65,000 annually, placing it out of reach for many without insurance.

‍

Lemtrada (Alemtuzumab): A Unique Immune System Modulator

• Mechanism: Targets specific immune cells attacking the body, mitigating MS symptoms.
• Administration: Two courses over two years; the first year involves five consecutive days, and the second year, three consecutive days.
• Monitoring: Essential to watch for side effects such as low white blood cell counts and infections.
• Effectiveness: Proven beneficial for many MS patients, though not suitable for all.
• Cost: Exceeds $120,000 annually, making it prohibitively expensive for uninsured individuals.

‍

Both Ocrevus and Lemtrada offer promising results for MS patients, significantly reducing the disease's impact. However, their high costs highlight the need for accessible healthcare solutions for those living with MS.

‍

Lemtrada vs Ocrevous

Ocrevus and Lemtrada, while belonging to distinct classes of medication, share certain side effects including upper respiratory infections, back pain, and limb pain. Ocrevus functions as a CD20-directed cytolytic antibody, contrasting with Lemtrada which is a recombinant humanized IgG1 kappa monoclonal antibody.

‍

Cost

• The annual cost of Lemtrada can be over $120,000 per year4. The average costs with Lemtrada increased from about $87,000 to nearly $180,000 in the first year and $108,000 in the second year1.
• The annual cost of Ocrevus can be over $65,000 per year45. The wholesale drug acquisition cost per package is $16,250 for Ocrevus2.

‍

Administration:

• Lemtrada is administered by intravenous infusion every three months4.
• Ocrevus is administered by intravenous infusion every six months45.

‍

Mechanism of Action:

• Lemtrada is an immunotherapy that stimulates the immune system to attack the MS lesions before they can cause damage to the nerves4.
• Ocrevus targets the B-cells in the immune system, which are believed to be responsible for the inflammation and nerve damage that occur with MS4.

‍

Side Effects:

• Lemtrada side effects can include low white blood cell counts and infections4.
• Ocrevus side effects can include rash, itching, hives, headache, nausea, and infusion-related reactions4.

‍

While both treatments have proven effective in reducing symptoms of MS, Lemtrada has a higher annual cost and requires more frequent infusions compared to Ocrevus. However, stem cell therapy is emerging as a potentially more affordable and effective treatment option for MS, with the ability to treat more aspects of the disease

‍

Advantages of stem cell therapy compared to traditional treatments.

Compared to traditional treatments like Ocrevus, stem cell therapy can potentially treat more aspects of Multiple Sclerosis (MS) and has a lower cost. Stem cell therapy can potentially treat the root cause of MS and its symptoms. While traditional treatments focus on managing the symptoms of MS, stem cell therapy has the potential to repair the damage done to the nerves to prevent the progression of MS.

In addition to treating the symptoms of MS, stem cell therapy could also be used to repair the damage done to the central nervous system. This could improve symptoms not affected by traditional treatments, such as bladder and bowel control, balance, energy levels, and strength.

Additionally, stem cell therapy does not need to be administered every month or every three months, as is the case with traditional treatments for MS. Instead, stem cell therapy is a one-time treatment that has the potential to provide lasting relief from MS symptoms. Due to the one-time nature of stem cell therapy, it has a lower overall cost than traditional treatments.

‍

Cost comparison of stem cell therapy vs. traditional treatments

The cost of traditional treatments for MS and their potential for long-term use can be high, as they are administered intravenously every 3 or 6 months. Stem cell therapy, on the other hand, is a one-time treatment that has the potential to last for years without requiring long-term use. Traditional therapies are expected to cost upwards of $120,000 annually, while stem cell therapy costs between $20,000 and $35,000 annually. While conventional treatments are expensive, and their long-term use can be costly, stem cell therapy costs may be lower than expected. 

When comparing the cost of stem cell therapy to the cost of traditional treatments for MS, it is essential to consider that conventional medicines are often only partially covered by insurance. This can result in a significant out-of-pocket expense for those receiving treatment, often making them more expensive than stem cell therapy.

‍

{{protocol2="/styling"}}

‍

Research and clinical trials for stem cell therapy

While stem cell therapy has shown promise in fighting the symptoms of MS and could provide an affordable alternative to traditional treatments, the FDA has not approved the treatment within the United States. However, there have been several preclinical and clinical trials that suggest the potential for stem cell therapy.

Preclinical trials have provided evidence that stem cells have the potential to repair and replace the myelin sheath surrounding the nerves. In preclinical trials, stem cells were found to promote the creation of new myelin sheath, improving the function of the damaged nerves and reducing symptoms of MS. Stem cell trials have also demonstrated the potential to reduce the frequency and duration of MS flare-ups.

Through these trials, stem cells were observed to affect the central nervous system and the immune system positively. These cells have been shown to combat and prevent the autoimmune attack on the nerves that causes MS.

‍

Conclusion

Stem cell therapy could be a promising treatment for MS, as it has shown potential to treat the root cause of MS and its symptoms. Traditional therapies for MS only focus on managing the symptoms of MS, but stem cell therapy has the potential o treat the cause of MS and its symptoms. There have been several preclinical and clinical trials that suggest its potential.

While the long-term stabilization effects of stem cell therapy are yet to be published, it has the potential to provide a more affordable alternative to traditional treatments for MS. Stem cell therapy could not only provide relief from MS symptoms but also provide a more cost-effective solution for long-term care.